BLIS Technologies Limited (BLT.NZ)
NZSE · NZD · Healthcare · Biotechnology
NZ$0.025 (+0.00%) as of
Key statistics
- Market cap
- 31.98M
- Forward P/E
- 13.37
- EPS (TTM)
- 0.0000
- Dividend yield
- 0.00%
- 52-week range
- 0.0140 – 0.0310
- Beta
- 0.61
- Revenue (TTM)
- 14.71M
- Profit margin
- 4.70%
- Volume
- 4.58k
About BLIS Technologies Limited
BLIS Technologies Limited develops and sells probiotics in New Zealand, the Asia Pacific, Europe, the Middle East, Africa, and North America. It offers BLIS K12, an oral probiotic that supports ear, nose, and throat health, as well as immunity and bad breath; BLIS M18, an oral probiotic for teeth and gums health; and BLIS Q24, a probiotic that balances the skin microbiome and restores skin's health. The company's products are used in various health areas, including ear, nose, throat, immune, dental, and skin, as well as pet oral. It exports its products. The company was formerly known as Tarn Holdings Limited and changed its name to BLIS Technologies Limited in August 2000. BLIS Technologies Limited was incorporated in 2000 and is headquartered in Dunedin, New Zealand.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Dunedin, New Zealand
- Employees
- 43
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.
Related stocks
- Australian Foundation Investmen (AFI.NZ)
- Trade Window Holdings Limited O (TWL.NZ)
- South Port New Zealand Limited (SPN.NZ)
- Minerals Exploration Limited Or (MEX.NZ)
- Burger Fuel Group Limited Ordin (BFG.NZ)
- Private Land and Property Fund (PLP.NZ)
- Third Age Health Services Limit (TAH.NZ)
- Smart Global Government Bond ET (GGB.NZ)